Dyclonine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dyclonine: From Topical Oral Anesthetic to Bronchitis
One-Sentence Summary
Dyclonine is a topical anesthetic commonly used in throat lozenges and oral sprays; no approved systemic indication is on file and the drug is not currently marketed in the United States. The TxGNN model predicts it may be effective for Bronchitis, but this prediction is currently supported by 0 clinical trials and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented (no approved indication on file; drug is currently unmarketed) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, dyclonine is a topical anesthetic commonly found in throat lozenges and oral sprays, where it blocks sensory nerve conduction in the pharyngeal/laryngeal mucosa via non-specific local anesthetic action to relieve throat irritation and cough sensation.
Bronchitis frequently presents with irritative cough as a core symptom, which gives a superficial, symptom-level rationale for this prediction. However, dyclonine’s local-anesthetic mechanism has no known effect on the airway inflammation or infection that underlies bronchitis pathology — at best it could mask the cough sensation rather than treat the disease. No mechanistic, preclinical, or clinical evidence currently supports this link beyond the TxGNN model score.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Dyclonine currently has no NDAs on file and is not marketed in the United States (0 licenses recorded).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction score is high (99.99%), but this is unsupported by any clinical trial, literature, or mechanistic evidence (Evidence Level L5) — the mechanistic link to bronchitis is indirect (symptomatic cough relief) rather than disease-modifying, and the drug is not currently marketed in the US.
To proceed, the following is needed:
- FDA/package-insert warnings and contraindications (currently a blocking data gap — required before any safety pre-assessment)
- Confirmed mechanism of action (MOA) data from DrugBank
- Preclinical or mechanistic studies directly linking dyclonine to airway/bronchial pathology
- For context, a lower-ranked candidate (irritable bowel syndrome, rank 10, score 99.93%) already has one mechanistic PubMed study (PMID 8907258) and reached L4/Research Question status — it may warrant earlier follow-up than bronchitis given the current evidence gap.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.